Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

Drug discovery services for oncology, immunology and neurodegenerative disease

Country of Origin: Netherlands
Reference Number: TONL20160727001
Publication Date: 27 July 2016

Summary

Dutch biotech company offers drug discovery services for oncology, immunology and neurodegenerative disease to pharmaceutical companies. The company translates novel biological concepts on the treatment of diseases into small molecule drug candidates. It has developed several  technology platforms which it offers to partners with a services agreement. The company is also looking for academic institutes for  research cooperation on new and innovative approaches for small molecule drug discovery.

Description

Developing and introducing new drugs is expensive. To reduce the cost and get medicines onto the market faster, universities and the pharmaceutical industry have to work together more effectively at every stage of the process. This Dutch biotech company bridges the innovation gap between pharmaceutical industries and universities by connecting its drug discovery expertise's (for example: assay development, screening, x-ray crystallography and medicinal chemistry) with disease biology know-how at academic centers. The founders of the company all worked for big pharma companies in the past. 

The company from the Netherlands has developed a number of proprietary technology platforms:
- Cancer cell line profiling and genomic biomarker discovery. This unique panel of cancer cell lines derived from a diverse set of human tumors can be used to develop personalized medicine for cancer or to identify the activity of a compound on tumour cells containing a defined variety of cancer genotypes.
- A platform for the discovery of novel synergistic drug combinations. Many therapies, particular in oncology, are applied as combination therapies. To identify the right combination of a lead compound with standards of care or new drugs this platform was developed.
- A method to determine the binding kinetics of protein kinase inhibitors, This service measures target residence time and kinetic selectivity reliably with short turn-around time.
- An assay technology for screening of the tryptophan metabolizing enzymes indoleamine-pyrrole 2,3-dioxygenase 1 (IDO1) and tryptophan dioxygenase (TDO). Tryptophan metabolism plays an important role in immune modulation and neurodegenerative disease. Tryptophan metabolizing enzymes are important drug targets for cancer immunotherapy and neurodegenerative disease. This technology was developed for high-throughput screening of tryptophan metabolizing enzymes.

The company is looking for pharmaceutical companies interested in using the above mentioned proprietary technology platforms in the framework of a services agreement. Preferred pharmaceutical partners have strong drug development capabilities and experience in the execution of clinic programs.
The company is also looking for accademic institutes for collaboration in the framework of research cooperation.

Advantages and Innovations

The technology for cancer cell line profiling and genomic biomarker discovery distinguishes itself from other cell panels by:
-Test range and data quality
-Rapid turnaround time
-Identification of genetic markers
-Comparative analysis with other cancer drugs
-Tissue and genetic makeup
-Low passage and culturing in original media

Stage Of Development

Already on the market

Requested partner

Pharmaceutical companies working in the fields of oncology, immunology and neurodegenerative disease are likely partners for a services agreement with this Dutch company.   

Academic institutes are also of interest for cooperation in the framework of research cooperation on new and innovative approaches for small molecule drug discovery.

Kooperationsanfrage stellen